Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 5:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,759 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Moderate Activity Clear all
Active, not recruiting Phase 3 Interventional

A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis

NCT06589986
View directory record Official record
Conditions
Moderately to Severely Active Ulcerative Colitis
Interventions
Afimkibart, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
16 Years to 80 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
58
States / cities
Dothan, Alabama • Lancaster, California • Orange, California + 49 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Sep 5, 2026, 5:24 PM EDT
Completed Not applicable Interventional

Neurostimulation for Cognitive Enhancement in Alzheimer's Disease

NCT04404153
View directory record Official record
Conditions
Alzheimer Disease, Dementia
Interventions
tDCS device model Soterix mini-CT (Soterix Medical Inc., New York, NY) programed to deliver active tDCS., tDCS device model Soterix mini-CT (Soterix Medical Inc., New York, NY) programed to deliver sham tDCS.
Device
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
60 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Sep 5, 2026, 5:24 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors

NCT04134728
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
GSK3196165 (Otilimab), Sarilumab, Placebo to GSK3196165/ Sarilumab, csDMARDs
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
46
States / cities
Mesa, Arizona • Phoenix, Arizona • Sun City, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2023 · Synced Sep 5, 2026, 5:24 PM EDT
Active, not recruiting Phase 3 Interventional

An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis

NCT03950232
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Etrasimod
Drug
Lead sponsor
Pfizer
Industry
Eligibility
16 Years to 80 Years
Enrollment
896 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
132
States / cities
Dothan, Alabama • Lake Elsinore, California • Lancaster, California + 44 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Sep 5, 2026, 5:24 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

The Effectiveness of Regular Exercise on Improving Sleep in Older Adults

NCT00149747
View directory record Official record
Conditions
Sleep Initiation and Maintenance Disorders, Sleep Disorders, Intrinsic
Interventions
Moderate-Intensity Aerobic Physical Activity, Health Education Class
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
55 Years and older
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2003
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 23, 2016 · Synced Sep 5, 2026, 5:24 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Philips AirFlosser Study

NCT01700348
View directory record Official record
Conditions
Gingivitis
Interventions
Airflosser, Manual Floss
Device
Lead sponsor
Tufts University
Other
Eligibility
18 Years to 70 Years
Enrollment
257 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 5, 2019 · Synced Sep 5, 2026, 5:24 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Step-up to Quit: Using Low-to-moderate Intensity Exercise for Reducing Smoking Cue Reactivity Among Low-income Smokers

NCT02220465
View directory record Official record
Conditions
Sedentary Lifestyle, Cigarette Smoking
Interventions
PA+ Smoking Cessation (LMPA), Standard Care Smoking Counseling (SCC)
Behavioral
Lead sponsor
Temple University
Other
Eligibility
18 Years to 59 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 19, 2014 · Synced Sep 5, 2026, 5:24 PM EDT
Completed Phase 2 Interventional Results available

The Safety & Efficacy of Combination BMS-201038 (AEGR-733) & Ezetimibe vs. Monotherapy in Moderate Hypercholesterolemia

NCT00405067
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
BMS-201038 (AEGR-733), Ezetimibe
Drug
Lead sponsor
Aegerion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 3, 2014 · Synced Sep 5, 2026, 5:24 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment

NCT04292730
View directory record Official record
Conditions
COVID-19
Interventions
Remdesivir, Standard of Care
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
12 Years and older
Enrollment
1,113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
106
States / cities
Anaheim, California • Berkeley, California • Burlingame, California + 76 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2021 · Synced Sep 5, 2026, 5:24 PM EDT
Completed Phase 3 Interventional Results available

Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) Treatment

NCT02873936
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Filgotinib, Placebo to match filgotinib, csDMARDs
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
449 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
55
States / cities
Huntsville, Alabama • Gilbert, Arizona • Covina, California + 52 more
Source: ClinicalTrials.gov public record
Updated May 12, 2021 · Synced Sep 5, 2026, 5:24 PM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)

NCT06979336
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
RO7837195, RO7837195 Matched Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
8
States / cities
Lancaster, California • San Diego, California • Colorado Springs, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 5, 2026, 5:24 PM EDT
Not yet recruiting Not applicable Interventional

Remotely Monitored, Mobile Health-supported, High Intensity Interval Training Before Hematopoietic Stem Cell Transplant

NCT06953648
View directory record Official record
Conditions
Hematopoietic Stem Cell Transplantation, Cardiorespiratory Fitness
Interventions
High Intensity Interval Training
Behavioral
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
3
States / cities
Kansas City, Kansas • Durham, North Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 30, 2025 · Synced Sep 5, 2026, 5:24 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Physical Activity in the Treatment of Obesity

NCT00615238
View directory record Official record
Conditions
Obesity
Interventions
Diet plus continuous bouts, Diet plus short bouts, Diet plus moderate lifestyle activity
Behavioral
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 60 Years
Enrollment
177 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2004
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 27, 2017 · Synced Sep 5, 2026, 5:24 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)

NCT06052059
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
IV Tulisokibart, IV Placebo, SC Tulisokibart, SC Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
16 Years to 80 Years
Enrollment
1,020 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
76
States / cities
Dothan, Alabama • Fairhope, Alabama • Litchfield Park, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Sep 5, 2026, 5:24 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Multicenter Study of 074-6751 Lotion in Subjects With Moderate Plaque Psoriasis

NCT03167515
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
074-6751 Lotion
Device
Lead sponsor
Ferndale Laboratories, Inc.
Industry
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
5
States / cities
Tampa, Florida • Carmel, Indiana • Plainfield, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2018 · Synced Sep 5, 2026, 5:24 PM EDT
Completed Phase 2 Interventional Results available

Break It Up: A Study Evaluating Breaking Up Daily Sedentary Behavior in Youth

NCT03223649
View directory record Official record
Conditions
Healthy, Obesity, Overweight
Interventions
Walking Bouts, Sedentary
Other
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
7 Years to 11 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Sep 5, 2026, 5:24 PM EDT
Completed Phase 2 Interventional

A Study Comparing the Analgesic Activity of Extended Release Hydrocodone/Acetaminophen (Vicodin® CR) and Placebo in Subjects With Pain Following Bunionectomy Surgery

NCT00404391
View directory record Official record
Conditions
Pain
Interventions
Hydrocodone/Acetaminophen Extended Release, Placebo
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 65 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
4
States / cities
Owing Mills, Maryland • Austin, Texas • San Marcos, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2011 · Synced Sep 5, 2026, 5:24 PM EDT
Completed Phase 3 Interventional Results available

A Controlled Study to Determine the Efficacy and Safety of CL-108 5 mg for Acute Pain and the Prevention of OINV

NCT03657810
View directory record Official record
Conditions
Pain, Nausea, Vomiting
Interventions
CL-108 5 mg, Norco, Placebo
Drug
Lead sponsor
Charleston Laboratories, Inc
Industry
Eligibility
18 Years and older
Enrollment
349 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
5
States / cities
Phoenix, Arizona • Pasadena, Maryland • Austin, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2023 · Synced Sep 5, 2026, 5:24 PM EDT
Terminated Phase 3 Interventional

The Efficacy and Safety of Cobitolimod in Participants With Moderate to Severe Active Left-Sided Ulcerative Colitis

NCT04985968
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Cobitolimod 250 mg, Cobitolimod 500 mg, Placebo
Drug
Lead sponsor
InDex Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
25
States / cities
Granada Hills, California • Mission Viejo, California • Rancho Cucamonga, California + 17 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2023 · Synced Sep 5, 2026, 5:24 PM EDT
Not yet recruiting No phase listed Observational

Exercise and Mortality in Middle-Aged and Older Adults

NCT07224659
View directory record Official record
Conditions
Overall Survival (All-cause Mortality)
Interventions
Control, Exercise
Behavioral
Lead sponsor
City of Hope Medical Center
Other
Eligibility
55 Years to 74 Years
Enrollment
19,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 5, 2026, 5:24 PM EDT
Terminated Phase 3 Interventional Results available

Open-Label Extension and Safety Study for Participants With Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144

NCT02403323
View directory record Official record
Conditions
Crohn Disease
Interventions
Etrolizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
790 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
59
States / cities
Arcadia, California • La Jolla, California • Long Beach, California + 51 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2024 · Synced Sep 5, 2026, 5:24 PM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Moderate to Severe Ulcerative Colitis

NCT05785715
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
NX-13 250mg, NX-13 750mg, NX-13 Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
11
States / cities
Miami, Florida • Orlando, Florida • Tampa, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Sep 5, 2026, 5:24 PM EDT
Completed Phase 3 Interventional Results available

JAK1 Inhibitor With Medicated Topical Therapy in Adolescents With Atopic Dermatitis

NCT03796676
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Placebo, PF-04965842, PF04965842
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years to 17 Years
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
52
States / cities
Birmingham, Alabama • Madera, California • Mission Viejo, California + 31 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2022 · Synced Sep 5, 2026, 5:24 PM EDT
Recruiting Phase 2 Interventional

A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis

NCT06598943
View directory record Official record
Conditions
Ulcerative Colitis, Ulcerative Colitis Chronic
Interventions
Eltrekibart, Mirikizumab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
46
States / cities
Chandler, Arizona • Little Rock, Arkansas • Chula Vista, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 5, 2026, 5:24 PM EDT